31st Jul 2019 14:29
(Alliance News) - Clinical development firm hVivo PLC on Wednesday said it is to start a new anti-mosquito trial, while its finance chief has also left.
hVivo is to start a trial at the University of Maryland School of Medicine for AGS-v Plus, an experimental vaccine designed to prevent a range of mosquito-borne diseases, such as malaria and zika virus.
The vaccine was created by Imutex Ltd, hVivo's joint venture with SEEK Group, of which it owns 49%.
Executive Chair Trevor Phillips said: "It is great to see the relationship with the National Institutes of Health and the University of Maryland School of Medicine continues as AGS-v PLUS, one of the assets in our joint venture Imutex, moves into the clinic."
"We are pleased the development of this asset is continuing with NIAID-funded researchers testing the vaccine and additional funding for the study by Innovate UK."
Elsewhere, Finance Director Shelley Fraser is to depart with immediate effect, with Corporate Finance Director Anesh Patel stepping up to the interim role.
Phillips said: "On behalf of the board I would like to thank Shelley for her contribution to the company and we wish her success in the future.
"We are pleased to be able to appoint Anesh as interim finance director who has worked at the company for a number of years and worked closely with Shelley and the finance team to ensure a smooth and effective transition."
hVivo shares were 0.1% lower on Wednesday afternoon in London at 19.72 pence each.
Related Shares:
hVIVO